CLINICAL_TRIALS
trial_result
· 2016-06-22
Clinical Trial Update: Capecitabine and Temozolomide for Neuroendocrine Cancers [Phase 2]
Summary
Phase 2 trial evaluating the combination of capecitabine and temozolomide in neuroendocrine tumors has completed with results posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Columbia University | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED | Results posted: 2016-06-22